Monitoring cancer therapy with PET: probably effective, but more research is needed

[1] Eisenhauer EA(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 11) Eur J Cancer 45 228-47

[2] Therasse P(2009)Monitoring response to therapeutic interventions in patients with cancer Semin Nucl Med. 39 210-32

[3] Bogaerts J(2009)FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas Clin Cancer Res. 15 2856-63

[4] Schwartz LH(2009)Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing Int J Radiat Oncol Biol Phys. 73 1228-34

[5] Sargent D(2009)Evaluation of chemotherapy response in osteosarcoma with FDG-PET Ann Nucl Med. 23 89-95

[6] Ford R(2009)Early prediction of response to first-line chemotherapy by sequential [ Ann Oncol. 20 1057-61

[7] Herrmann K(2009)F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer Eur Radiol. 19 1347-57

[8] Krause BJ(2009)The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Eur J Cancer 45 290-9

[9] Bundschuh RA(2009)Validation of novel imaging methodologies for use as cancer clinical trial end-points Clin Cancer Res. 15 1891-7

[10] Dechow T(2009)Considerations for the use of imaging tools for phase II treatment trials in oncology Q J Nucl Med Mol Imaging 53 158-66

[1] Eisenhauer EA(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 11) Eur J Cancer 45 228-47

[2] Therasse P(2009)Monitoring response to therapeutic interventions in patients with cancer Semin Nucl Med. 39 210-32

[3] Bogaerts J(2009)FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas Clin Cancer Res. 15 2856-63

[4] Schwartz LH(2009)Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing Int J Radiat Oncol Biol Phys. 73 1228-34

[5] Sargent D(2009)Evaluation of chemotherapy response in osteosarcoma with FDG-PET Ann Nucl Med. 23 89-95

[6] Ford R(2009)Early prediction of response to first-line chemotherapy by sequential [ Ann Oncol. 20 1057-61

[7] Herrmann K(2009)F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer Eur Radiol. 19 1347-57

[8] Krause BJ(2009)The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Eur J Cancer 45 290-9

[9] Bundschuh RA(2009)Validation of novel imaging methodologies for use as cancer clinical trial end-points Clin Cancer Res. 15 1891-7

[10] Dechow T(2009)Considerations for the use of imaging tools for phase II treatment trials in oncology Q J Nucl Med Mol Imaging 53 158-66